Phosphodiesterase 5 inhibition improves beta-cell function in metabolic syndrome.

Hill KD, Eckhauser AW, Marney A, Brown NJ
Diabetes Care. 2009 32 (5): 857-9

PMID: 19196886 · PMCID: PMC2671107 · DOI:10.2337/dc08-1862

OBJECTIVE - This study tested the hypothesis that phosphodiesterase 5 inhibition alone or in combination with ACE inhibition improves glucose homeostasis and fibrinolysis in individuals with metabolic syndrome.

RESEARCH DESIGN AND METHODS - Insulin sensitivity, beta-cell function, and fibrinolytic parameters were measured in 18 adults with metabolic syndrome on 4 separate days after a randomized, crossover, double-blind, 3-week treatment with placebo, ramipril (10 mg/day), tadalafil (10 mg o.d.), and ramipril plus tadalafil.

RESULTS - Ramipril decreased systolic and diastolic blood pressure, ACE activity, and angiotensin II and increased plasma renin activity. Ramipril did not affect insulin sensitivity or beta-cell function. In contrast, tadalafil improved beta-cell function (P = 0.01). This effect was observed in women (331.9 +/- 209.3 vs. 154.4 +/- 48.0 32 micro x mmol(-1) x l(-1), respectively, for tadalafil treatment vs. placebo; P = 0.01) but not in men. There was no effect of any treatment on fibrinolysis. CONCLUSIONS Phosphodiesterase 5 inhibition may represent a novel strategy for improving beta-cell function in metabolic syndrome.

MeSH Terms (16)

Adult Angiotensin-Converting Enzyme Inhibitors Blood Pressure Carbolines Cross-Over Studies Double-Blind Method Female Humans Insulin-Secreting Cells Male Metabolic Syndrome Phosphodiesterase 5 Inhibitors Phosphodiesterase Inhibitors Ramipril Renin Tadalafil

Connections (1)

This publication is referenced by other Labnodes entities: